drugset / Trial / NCT00069706

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

NCT00069706

Phase 2 Completed 118 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2003-07
Primary completion
2003-10
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AL-12182 Small molecule 0.003 % Other
Subject AL-12182 Small molecule 0.01 % Other
Subject AL-12182 Small molecule 0.03 % Other
Comparator Latanoprost Small molecule 0.005 % Other